Abstract
Objectives: To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study. Methods: Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP). Results: Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction. Conclusion: Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.
| Original language | English |
|---|---|
| Journal | Modern Rheumatology |
| DOIs | |
| Publication status | Accepted/In press - 2015 Oct 9 |
Fingerprint
Keywords
- Golimumab
- High disease activity
- Japanese
- Rheumatoid arthritis
- Total Sharp score
ASJC Scopus subject areas
- Rheumatology
Cite this
Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels : Post hoc analysis of the GO-FORTH study. / Tanaka, Yoshiya; Harigai, Masayoshi; Takeuchi, Tsutomu; Yamanaka, Hisashi; Ishiguro, Naoki; Yamamoto, Kazuhiko; Ishii, Yutaka; Nakajima, Hiroshi; Baker, Daniel; Miyasaka, Nobuyuki; Koike, Takao.
In: Modern Rheumatology, 09.10.2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels
T2 - Post hoc analysis of the GO-FORTH study
AU - Tanaka, Yoshiya
AU - Harigai, Masayoshi
AU - Takeuchi, Tsutomu
AU - Yamanaka, Hisashi
AU - Ishiguro, Naoki
AU - Yamamoto, Kazuhiko
AU - Ishii, Yutaka
AU - Nakajima, Hiroshi
AU - Baker, Daniel
AU - Miyasaka, Nobuyuki
AU - Koike, Takao
PY - 2015/10/9
Y1 - 2015/10/9
N2 - Objectives: To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study. Methods: Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP). Results: Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction. Conclusion: Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.
AB - Objectives: To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study. Methods: Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP). Results: Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction. Conclusion: Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.
KW - Golimumab
KW - High disease activity
KW - Japanese
KW - Rheumatoid arthritis
KW - Total Sharp score
UR - http://www.scopus.com/inward/record.url?scp=84945242829&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945242829&partnerID=8YFLogxK
U2 - 10.3109/14397595.2015.1086041
DO - 10.3109/14397595.2015.1086041
M3 - Article
C2 - 26471830
AN - SCOPUS:84945242829
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
ER -